Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of July 2025. The report details the results of a special meeting of shareholders held on July 28, 2025, in Taizhou, Jiangsu, China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes
The primary material change reported is the approval of a dual-class share structure:
- Creation of Class B Shares: A new class of unlimited Class B Ordinary Shares was created, granting holders 50 votes per share.
- Re-designation of Shares: 532 existing shares held by Feng Zhou Management Limited were re-designated as Class B Ordinary Shares. The remaining 116,027,226 shares were re-designated as Class A Ordinary Shares (1 vote per share).
- Corporate Governance: The Company's Memorandum and Articles of Association were amended to reflect these changes.
Voting Results and Management Commentary
A quorum was established with 39,648,847 shares voted out of 116,027,758 issued and outstanding. The proposal to create the new share class and amend the Articles of Association was approved with the following vote count:
- For: 39,642,273
- Against: 6,445
- Abstain: 129
The filing does not contain forward-looking guidance, risk factors, or management commentary regarding future operations beyond the structural changes.
Investor Verification Checklist
- Verify the effective date of the New Amended Memorandum and Articles of Association upon filing with the British Virgin Islands Companies Registry.
- Confirm the specific voting rights and conversion privileges of the newly created Class B Ordinary Shares.
- Review the full text of Exhibit 3.1 for detailed rights and restrictions associated with the dual-class structure.